Caitong International Asset Management’s Sonoma Pharmaceuticals SNOA Stock Holding History

Caitong International Asset Management’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2	Buy	+1	New	+$3	﹤0.01%	2431

Other funds holding SNOA

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

MCWS

McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caitong International Asset Management's SNOA Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Sonoma Pharmaceuticals (SNOA) in Q1 2026: 1 share worth $2. The stake represents ﹤0.01% of the portfolio and ranks #2431 among its holdings.

17 funds tracked by Wall St. Rank hold SNOA as of Q1 2026.

Caitong International Asset Management held 1 share of Sonoma Pharmaceuticals worth $2 as of Q1 2026.
Sonoma Pharmaceuticals was a new Caitong International Asset Management position in Q1 2026.
Sonoma Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2431 holding.
17 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.